Teladoc Health, INC

Teladoc Health announced the appointment of Mark V. Anquillare, former COO of Verisk Analytics, to its board of directors, enhancing its financial and strategic oversight.

Teladoc Health, Inc. announced the results of its 2026 Annual Meeting of Stockholders, with all director nominees elected and executive compensation approved.

Teladoc Health reported a 2% year-over-year revenue decrease to $613.8 million for Q1 2026, with a net loss of $63.8 million, though the net loss per share improved significantly.

Teladoc Health announced the appointment of Susan R. Salka, former AMN Healthcare CEO, to its Board of Directors and key committees.

Teladoc Health reported a significantly reduced full-year net loss and flat fourth-quarter revenue, with mixed segment performance.

Teladoc Health, Inc. announced that director Thomas G. McKinley will retire from its Board effective February 20, 2026, citing personal reasons.

Teladoc Health reported a 4% revenue decrease in Q2 2026, driven by a strategic shift in its BetterHelp segment towards insurance-covered services, impacting overall financial performance.

Teladoc Health reports a 2% revenue decrease for Q3 2025, alongside significant goodwill impairments and a net loss, despite growth in U.S. Integrated Care members.

Teladoc Health, a global leader in virtual care, reported a significantly reduced net loss for the second quarter and first half of 2025, primarily due to lower goodwill impairment charges, despite a slight decline in overall revenue driven by its BetterHelp segment.

Teladoc Health's Q1 2025 revenue decreased by 3% year-over-year, impacted by BetterHelp performance and a significant goodwill impairment charge.

Teladoc Health's Q3 2024 results show a slight revenue decrease and a significant goodwill impairment charge, impacting overall profitability.

Teladoc Health's Q2 2024 results reveal a significant $790 million goodwill impairment charge, impacting overall profitability despite some revenue growth in the Integrated Care segment.

Teladoc Health, the virtual care leader, reported a net loss of $200.3 million in 2025, a significant improvement from 2024, despite a 2% overall revenue decrease driven by its BetterHelp segment.

Teladoc Health's 2024 annual report reveals a mix of strategic progress and financial headwinds, including a significant goodwill impairment charge.

Teladoc Health files an executive severance agreement amendment and details its non-employee director compensation program, outlining terms for severance, equity awards, and cash retainers.

Teladoc Health, Inc. reports a Form 4 filing detailing a stock transaction by Kelly Bliss, President of U.S. Group Health, executed under a pre-arranged trading plan.

Joseph Catapano, Chief Accounting Officer at Teladoc Health, reported transactions involving restricted stock units and common stock sales.

Teladoc Health, Inc. reports a transaction where President of U.S. Group Health, Kelly Bliss, sold 2,500 shares of common stock on July 1, 2026, as part of a pre-arranged 10b5-1 trading plan.

Teladoc Health's President of U.S. Group Health, Kelly Bliss, has sold 2,500 shares of common stock as part of a pre-arranged trading plan.

Teladoc Health CEO Charles Divita acquired 42,802 shares via equity vesting and sold 18,074 shares to cover tax obligations.

Fernando M. Rodrigues, President of BetterHelp at Teladoc Health, Inc., reported a sale of 9,572 shares of common stock executed on June 3, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Teladoc Health announces its 2026 Annual Meeting of Stockholders, detailing director nominations, executive compensation vote, and auditor ratification.

Teladoc Health is soliciting stockholder votes for the approval of executive compensation (Say-on-Pay Proposal) and an amendment to the 2023 Incentive Award Plan at the upcoming Annual Meeting on May 22, 2025.

Teladoc Health, Inc. has filed a definitive proxy statement with the SEC.

Teladoc Health is asking stockholders to approve an amendment to its 2023 Incentive Award Plan to increase the number of shares available for issuance by 6,850,000 shares, aiming to attract, motivate, and retain qualified personnel.

Teladoc Health will hold its annual stockholder meeting on May 23, 2024, and has made proxy materials available for review.

Teladoc Health's upcoming annual meeting will address director elections, executive compensation, auditor ratification, and other corporate matters.

Vanguard Capital Management has reported beneficial ownership of 9,205,306 shares, representing 5.16% of Teladoc Health's common stock as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 6.97% in Teladoc Health Inc. common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G for Teladoc Health Inc., reporting 0% beneficial ownership following an internal corporate realignment.

Point72 Asset Management, along with affiliates, reported a 3.3% passive beneficial ownership stake in Teladoc Health, Inc., totaling 5,795,178 shares.

The Vanguard Group has reported a beneficial ownership of 11.98% of Teladoc Health Inc.'s common stock, holding over 21 million shares as a passive investment.

Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have jointly disclosed a beneficial ownership of 5.0% in Teladoc Health, Inc., totaling 8,826,350 shares.